These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162 [TBL] [Abstract][Full Text] [Related]
6. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice. Li D; Zhang H; Zhong Y Biochem Biophys Res Commun; 2018 Apr; 498(3):388-394. PubMed ID: 28847729 [TBL] [Abstract][Full Text] [Related]
7. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice. Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336 [TBL] [Abstract][Full Text] [Related]
8. Hepatic Meteorin-like and Krüppel-like Factor 3 are Associated with Weight Loss and Liver Injury. Grander C; Grabherr F; Enrich B; Meyer M; Mayr L; Schwärzler J; Pedrini A; Effenberger M; Adolph TE; Tilg H Exp Clin Endocrinol Diabetes; 2022 Jun; 130(6):406-414. PubMed ID: 34407548 [TBL] [Abstract][Full Text] [Related]
9. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Wang Y; Chen C; Chen J; Sang T; Peng H; Lin X; Zhao Q; Chen S; Eling T; Wang X Redox Biol; 2022 Jun; 52():102322. PubMed ID: 35504134 [TBL] [Abstract][Full Text] [Related]
11. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. Moschen AR; Wieser V; Gerner RR; Bichler A; Enrich B; Moser P; Ebenbichler CF; Kaser S; Tilg H J Hepatol; 2013 Dec; 59(6):1315-22. PubMed ID: 23928404 [TBL] [Abstract][Full Text] [Related]
12. Adipose type I interferon signalling protects against metabolic dysfunction. Wieser V; Adolph TE; Grander C; Grabherr F; Enrich B; Moser P; Moschen AR; Kaser S; Tilg H Gut; 2018 Jan; 67(1):157-165. PubMed ID: 28011892 [TBL] [Abstract][Full Text] [Related]
13. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Mullican SE; Lin-Schmidt X; Chin CN; Chavez JA; Furman JL; Armstrong AA; Beck SC; South VJ; Dinh TQ; Cash-Mason TD; Cavanaugh CR; Nelson S; Huang C; Hunter MJ; Rangwala SM Nat Med; 2017 Oct; 23(10):1150-1157. PubMed ID: 28846097 [TBL] [Abstract][Full Text] [Related]
15. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Jorge ASB; Andrade JMO; Paraíso AF; Jorge GCB; Silveira CM; de Souza LR; Santos EP; Guimaraes ALS; Santos SHS; De-Paula AMB Obes Res Clin Pract; 2018; 12(Suppl 2):1-8. PubMed ID: 27083404 [TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 15 increases following oral glucose ingestion: effect of meal composition and obesity. Schernthaner-Reiter MH; Kasses D; Tugendsam C; Riedl M; Peric S; Prager G; Krebs M; Promintzer-Schifferl M; Clodi M; Luger A; Vila G Eur J Endocrinol; 2016 Dec; 175(6):623-631. PubMed ID: 27926473 [TBL] [Abstract][Full Text] [Related]
17. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Moschen AR; Molnar C; Enrich B; Geiger S; Ebenbichler CF; Tilg H Mol Med; 2011; 17(7-8):840-5. PubMed ID: 21394384 [TBL] [Abstract][Full Text] [Related]
18. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Chen Z; Wang GX; Ma SL; Jung DY; Ha H; Altamimi T; Zhao XY; Guo L; Zhang P; Hu CR; Cheng JX; Lopaschuk GD; Kim JK; Lin JD Mol Metab; 2017 Aug; 6(8):863-872. PubMed ID: 28752050 [TBL] [Abstract][Full Text] [Related]
19. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Yang L; Chang CC; Sun Z; Madsen D; Zhu H; Padkjær SB; Wu X; Huang T; Hultman K; Paulsen SJ; Wang J; Bugge A; Frantzen JB; Nørgaard P; Jeppesen JF; Yang Z; Secher A; Chen H; Li X; John LM; Shan B; He Z; Gao X; Su J; Hansen KT; Yang W; Jørgensen SB Nat Med; 2017 Oct; 23(10):1158-1166. PubMed ID: 28846099 [TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity. Galuppo B; Agazzi C; Pierpont B; Chick J; Li Z; Caprio S; Santoro N Nutr Diabetes; 2022 Feb; 12(1):9. PubMed ID: 35194014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]